Jerome D. Jabbour
Chief Executive Officer
Mr. Jabbour is Chief Executive Officer of Matinas BioPharma. He served as President since March 2016 and since October 2013, he served as Executive Vice President, Chief Business Officer and General Counsel. Mr. Jabbour has extensive experience in the pharmaceutical and healthcare industries, both domestically and internationally. Previously he served as Executive Vice President, General Counsel & Secretary of MediMedia, a diversified health care services company. Prior to MediMedia, he was the Senior Vice President and Head of Global Legal Affairs for Wockhardt Limited, a global pharmaceutical and biotechnology company. Immediately prior to that, he served as Commercial Counsel and Assistant Secretary for Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary. Earlier in his career, he held positions as counsel at Alpharma and in private practice at Lowenstein Sandler, PC. Mr. Jabbour earned his J.D. from Seton Hall University School of Law in Newark, New Jersey and a B.A. in Psychology from Loyola University in Baltimore, Maryland.
Theresa Matkovits, Ph.D.
Chief Development Officer
Dr. Matkovits joined Matinas as Chief Development Officer in October 2018. She brings extensive global drug development and commercialization experience with vast expertise ranging from large global multinational pharmaceutical companies to mid-size and small biotech settings and spans all phases of drug development including bringing to market a number of globally-approved and registered products and late-stage products including biologics, small molecules, and devices across multiple therapeutic areas.
Previously Dr. Matkovits served as the Chief Operating Officer of ContraVir Pharmaceuticals (NASDAQ: CTRV) where she was instrumental in the establishment and build-out of its global development organization with responsibility and oversight for Clinical Development, Regulatory, Manufacturing, Quality, and Project Management functions, including the leadership of the global development efforts for the company's antiviral portfolio. Prior to that, Dr. Matkovits served as Global Program Leader at NPS Pharmaceuticals where she led the integration of two commercial assets acquired from Takeda into NPS, and led the company in the successful approval of Natpara in the U.S. During her tenure, Dr. Matkovits was a key contributor in the expansion of NPS from a U.S.-centric to a global development and commercial organization. Prior to her time at NPS, Dr. Matkovits was Vice President, Innovation Leader at the Medicines Company (NASDAQ: MDCO), where she led the successful global development and registration of oritavancin, which is now approved and commercialized in the U.S. and EU as ORBACTIV. Earlier in her career, Dr. Matkovits held a number of global leadership positions at Novartis across Global Development and the U.S. Commercial Organization, including as Head, Strategic Planning and Operations, U.S. Medical and Drug Regulatory Affairs.
Dr. Matkovits serves on the Board of Directors of BioSurplus and also serves as an Independent Director of Aradigm Corporation (NASDAQ: ARDM) Dr. Matkovits was recently appointed to serve on the Board of Appili Therapeutics. Dr. Matkovits was selected to participate in Women in Bio's Boardroom Ready Program in 2016. Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of NJ.
Raphael J. Mannino, Ph.D.
Chief Scientific Officer
Dr. Mannino is an internationally recognized expert in the use of artificial lipid-based structures for the formulation and delivery of biologicals and pharmaceuticals, and has pioneered the use of lipid nano-crystal technology for this purpose. He is a co-inventor of the proprietary, disruptive lipid nano-crystal technology utilized by Matinas BioPharma to encapsulate existing drugs, making them safer, more tolerable, less toxic and orally available. Dr. Mannino has been a member of Matinas BioPharma's Scientific Advisory Board since January 2015, and was an Associate Professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School from 1990 until August 2015.
Previously, Dr. Mannino was the founder of BioDelivery Sciences, Inc., and served as its President, Chief Executive Officer and Chief Scientific Officer and as a member of its Board of Directors from 1995 to 2000, when it was acquired by BioDelivery Sciences International, Inc. (BDSI). He served as BDSI's Executive Vice President and Chief Scientific Officer from 2001 to 2009, and was a member of its Board of Directors from 2000 to 2007. In addition to his experience at BDSI, Dr. Mannino was an Assistant, then Associate Professor, at Albany Medical College from 1980 to 1990, and an Instructor and then an Assistant Professor at Rutgers Medical School from 1977 to 1980. He completed his postdoctoral training from 1973 to 1976 at the Biocenter in Basel, Switzerland and received his Ph.D. in Biological Chemistry in 1973 from the Johns Hopkins University, School of Medicine.
Keith A. Kucinski, CPA, MBA
Chief Financial Officer
Mr. Kucinski is Chief Financial Officer of Matinas BioPharma. He is a seasoned healthcare professional with over 20 years of diversified and broad finance expertise with demonstrated leadership and success in financial and strategic planning, accessing the capital markets and mergers and acquisitions across the healthcare and business consulting industries.
Mr. Kucinski joins Matinas BioPharma having most recently served as Chief Financial Officer at RemedyOne, a privately held healthcare consulting organization. While serving at RemedyOne, he led initiatives to support the ambitious objectives of this rapidly growing company and position RemedyOne for the next stage in its life-cycle. Prior to that, he served as Vice President & Treasurer at Par Pharmaceutical Companies, Inc., an operating company of Endo International plc (NASDAQ: ENDP), a leading generics and specialty-branded pharmaceutical company with revenues in excess of $1 billion. As a key member of the leadership team at Par, Keith played an instrumental role in the acquisition of Par by Endo for more than $8 billion in 2015. Additionally, Mr. Kucinski held various roles at Barr Pharmaceuticals, Inc., including Senior Director, Finance & Corporate Development and Assistant Treasurer & Senior Director, Finance. During his time at Barr Pharmaceuticals, Mr. Kucinski played an integral role in the $2.5 billion acquisition and successful integration of a European pharmaceutical company.
Mr. Kucinski is a Certified Public Accountant. He received his Bachelor of Business Administration in Accounting from the University of Notre Dame and an M.B.A. in Finance & Management from the Leonard N. Stern School of Business at New York University.